Closing Bell: Healthcare sector gives ASX a booster to rise 0.33pc
CSL adds 2.4pc as UBS marks ASX healthcare sector as best EPS pick
Chinese manufacturing data contracts, but shows signs of stirring
Are healthcare bulls returning?
The ASX healthcare sector was the best performing of the ASX's 11 subcategories in trade today, handily outperforming the other sectors with a 1.58% jump.
With support from industrials (+1%) and consumer discretionary (+0.98%), that was enough for the ASX 200 to make a convincing gain of 0.33% today, having had a steady run of momentum throughout trade.
Regis Healthcare (ASX:REG) added 3.2%, Ramsay Health Care (ASX:RHC) 1.9% and Summerset Group (ASX:SNZ) 1.3%.
As for our healthcare giants, CSL (ASX:CSL) gained 2.4%, Pro Medicus (ASX:PME) 2% and Cochlear (ASX:COH) 1.7%.
If financial giant UBS is to be believed, this may be the start of a bit of a bullish run for ASX biotech stocks, which have been suffering over the past few months.
UBS reckons the ASX healthcare sector is now undervalued, offering the best earnings-per-share growth of all sectors, and forecasting a 20% increase in the 2025-26 year.
'Investor sentiment towards the healthcare sector has broadly cooled over the past year, with some marked deterioration seen across many stocks,' UBS says.
'Cochlear in particular has seen investor apathy build over the last year, which represents a significant change of views.'
Back on the ASX today, the main drag was in the materials sector, down 0.77%.
The ASX 200 Resources index was also an anchor, shedding 0.96%, but it was outweighed by gains in the All Tech, Gold and Small Ords indices.
Chinese manufacturing data contracts again
While iron ore has been enjoying a small uptick in pricing the past five days or so, the latest data out of China isn't the best news for Aussie base metal stocks.
Manufacturing activity from our largest trading partner fell again for a third month straight in June, despite Beijing's attempts to stimulate the sector.
The official purchasing manager's index did improve slightly from 49.5 in May to 49.7 in June, but remained below the 50-point benchmark which indicates whether the index is expanding or contracting.
Inventory and employment levels at factories fell as well, but the news wasn't all bad.
The sub-index tracking manufacturing production rose to 51 and new orders lifted to 50.2, which could indicate the first stirrings of momentum beginning to build in China's industrial activity.
Chinese Premier Li Qiang said Chinese authorities would implement measures to 'make China a mega-sized consumption powerhouse' as well as a manufacturing one in a speech at the World Economic Forum's annual conference in China.
'We still think that there are challenges this year, but I think it's not as far-fetched as we thought before,' Oxford Economics lead economist for China Louise Loo said.
'However punitive tariffs are, I think in the near term, it's quite hard to decouple China from global supply chains, and that means we will continue to see China exports, at least, remain quite competitive, and that should support economic growth for the Chinese.'
It remains to be seen if that will translate into higher demand for Australian iron ore, but one can hope.
ASX SMALL CAP LEADERS
Today's best performing small cap stocks:
Security Name Last % Change Volume Market Cap
WEL Winchester Energy 0.002 100% 165600 $1,363,019
LSR Lodestar Minerals 0.011 83% 42455380 $1,910,543
ADD Adavale Resource Ltd 0.0015 50% 15489651 $2,287,279
ADY Admiralty Resources. 0.006 50% 1690337 $10,517,918
EEL Enrg Elements Ltd 0.0015 50% 860601 $3,253,779
MPR Mpower Group Limited 0.01 43% 5225088 $2,405,923
GTE Great Western Exp. 0.011 38% 3625782 $4,542,063
MEG Megado Minerals Ltd 0.023 35% 4786016 $10,313,615
ALM Alma Metals Ltd 0.004 33% 2325000 $5,261,182
FCT Firstwave Cloud Tech 0.016 33% 3070713 $20,562,224
FHS Freehill Mining Ltd. 0.004 33% 15028446 $10,241,561
GTR Gti Energy Ltd 0.004 33% 5538733 $8,996,849
SPX Spenda Limited 0.008 33% 16838995 $27,691,293
GLH Global Health Ltd 0.068 33% 176778 $2,987,301
AAU Antilles Gold Ltd 0.005 25% 6046776 $9,516,272
ERL Empire Resources 0.005 25% 692641 $5,935,653
RCM Rapid Critical 0.0025 25% 1125000 $2,831,556
ROG Red Sky Energy. 0.005 25% 120000 $21,688,909
TMX Terrain Minerals 0.0025 25% 5339766 $5,063,629
VR1 Vection Technologies 0.036 24% 40421798 $51,255,235
THR Thor Energy PLC 0.011 22% 2677843 $6,397,109
KNB Koonenberrygold 0.039 22% 46537381 $32,790,159
RPG Raptis Group Limited 0.063 21% 185561 $18,235,612
NGX Ngxlimited 0.145 21% 45773 $10,873,421
SDV Scidev Ltd 0.36 20% 293999 $57,026,459
Making news…
Lodestar Minerals (ASX:LSR) is looking to follow up on gold hits at its Chilean copper-gold projects with proceeds from a $2.2m two-tranche share placement.
LSR is offering $475k in the first tranche to clients of lead manager Oakley Capital Partners, with the rest hanging on shareholder approval.
Adavale Resources (ASX:ADD) is preparing to put drill bit to ground at the London Victoria Mine in NSW, which historically produced gold grades up to 43.8 g/t gold.
It's the first exploration at the mine in 30 years; ADD will target shallow extensions to the existing mineral resource estimate, which currently sits at 115,000 ounces of gold.
FirstWave Cloud Technology (ASX:FCT) has inked a licensing agreement with Claro Dominican Republic to license its NMIS v9 network management software suite for an upfront fee of US$250k.
It's a pure-profit contract, as the contract doesn't require delivery, support or professional services.
GTI Energy (ASX:GTR) is locking in a $4.5m placement at an issue price of 0.035 cents a share, a 16.7% premium to the last close price of 0.030 cents. The money will be funnelled directly to resource expansion and infill drilling at the Lo Herma uranium project.
GTR's recent scoping study revealed a potential pre-tax net present value of between $174m and $187m and an internal rate of return of between 52% and 66% for Lo Herma. Check out Stockhead's Break it Down for more on GTR's capital raising.
Spenda (ASX:SPX) has teamed up with APG Pay Pty Ltd to develop and commercialise a corporate credit platform.
The two companies will collab on a scaleable B2B payments space that can scale across multiple industries, starting with the travel industry. Spenda reckons the deal will bring in recurring profit of $1.7m per year.
ASX SMALL CAP LAGGARDS
Today's worst performing small cap stocks:
Security Name Last % Change Volume Market Cap
CT1 Constellation Tech 0.001 -50% 1322698 $2,949,467
IS3 I Synergy Group Ltd 0.002 -50% 3892995 $2,002,920
T3D 333D Limited 0.006 -33% 33333 $1,585,651
ADR Adherium Ltd 0.004 -33% 3436600 $5,390,874
TEG Triangle Energy Ltd 0.002 -33% 4164703 $6,267,702
TKL Traka Resources 0.001 -33% 135263 $3,188,685
L1M Lightning Minerals 0.043 -28% 1471249 $6,199,699
ZMM Zimi Ltd 0.008 -27% 616731 $4,702,982
FIN FIN Resources Ltd 0.003 -25% 557800 $2,779,554
GMN Gold Mountain Ltd 0.0015 -25% 1983598 $11,239,518
HLX Helix Resources 0.0015 -25% 1234287 $6,728,387
SFG Seafarms Group Ltd 0.0015 -25% 893383 $9,673,198
SRN Surefire Rescs NL 0.0015 -25% 334051 $4,972,891
TYX Tyranna Res Ltd 0.003 -25% 325000 $13,153,701
GLA Gladiator Resources 0.007 -22% 1626499 $6,824,671
YAR Yari Minerals Ltd 0.012 -20% 2978290 $8,320,672
AUK Aumake Limited 0.002 -20% 1177734 $7,558,397
MEM Memphasys Ltd 0.004 -20% 6329063 $9,917,991
MKL Mighty Kingdom Ltd 0.016 -20% 1737419 $10,326,928
PPG Pro-Pac Packaging 0.016 -20% 78233 $3,633,754
RAN Range International 0.002 -20% 2187661 $2,348,226
SKK Stakk Limited 0.004 -20% 2620995 $10,375,398
VEN Vintage Energy 0.004 -20% 1780465 $10,434,568
HIQ Hitiq Limited 0.014 -18% 1054211 $7,814,865
BDM Burgundy D Mines Ltd 0.029 -17% 604995 $49,746,630
IN CASE YOU MISSED IT
QPM Energy (ASX:QPM) is powering up with plans for a new gas-fired plant at the Isaac Energy Hub.
Astute Metals (ASX:ASE) has identified four high-priority gold-silver targets at its Needles project in Nevada, USA, thanks to a data review.
Green Critical Minerals (ASX:GCM) has cleared another hurdle at the McIntosh graphite project with a PFS showcasing robust economics including $25m post-tax NPV, 25.3% IRR and a 32.5-year mine life.
LTR Pharma (ASX:LTP) has completed extractables studies for its Spontan intranasal spray for erectile dysfunction and kicked off a leachables study.
Ausgold (ASX:AUC) has released a positive definitive feasibility study for its Katanning gold project (KGP) in WA, highlighting robust returns over a 10-year mine life.
Theta Gold Mines' (ASX:TGM) board has rubber stamped the TGME mine in South Africa's Mpumalanga region as high gold prices stir investment in the historic mining district.
Break it Down: Anson Resources (ASX:ASN) has paired up with a Korean battery maker to develop a DLE demonstration plant at the Green River project in Utah.
Redcastle Resources (ASX:RC1) is on its way to becoming an integrated exploration and production company after lifting resources to 42,000oz at the Redcastle project.
TRADING HALTS
Australian Mines (ASX:AUZ) – cap raise and potential acquisition
AuKing Mining (ASX:AKN) – cap raise
Battery Age Minerals (ASX:BM8) – cap raise
Blackstone Minerals (ASX:BSX) – cap raise
archTIS (ASX:AR9) – cap raise
Lodestar Minerals (ASX:LSR) – cap raise
Liontown Resources (ASX:LTR) – executive changes
Olympio Metals (ASX:OLY) – cap raise
Peak Minerals (ASX:PUA) – response to ASX price query
Red Mountain Mining (ASX:RMX) – cap raise
Rent.com.au (ASX:RNT) – cap raise
Terra Uranium (ASX:T92) – acquisition and cap raise
Vitasora Health (ASX:VHL) – cap raise
At Stockhead, we tell it like it is. While GTI Energy is a Stockhead advertiser, it did not sponsor this article.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
22 minutes ago
- News.com.au
Top 10 at 11: ASX jumps on open as copper and battery metals rally
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Resources drive early gains The ASX 200 has jumped 0.42% in the first half hour of trading, with 9 of 11 sectors making gains as of about 10:30 am AEST. The materials sector is leading the charge, building on momentum generated by a rally in lithium and battery metal stocks and a 5.9% jump in James Hardie (ASX:JHX) shares. The construction materials company completed its acquisition of NYSE-listed outdoor living business AZEK today, adding to its extensive portfolio of exterior design brands. Lithium, rare earth and copper stocks are making the biggest moves this morning, including several of the stocks on our small cap winners list… WINNERS Code Name Last % Change Volume Market Cap PKO Peako Limited 0.003 50% 120000 $2,975,484 EEL Enrg Elements Ltd 0.002 33% 792525 $4,880,668 IS3 I Synergy Group Ltd 0.002 33% 620409 $2,253,285 SRN Surefire Rescs NL 0.002 33% 1500000 $3,729,668 LAT Latitude 66 Limited 0.029 26% 10932 $3,298,216 ADG Adelong Gold Limited 0.005 25% 60000 $8,274,707 DY6 Dy6Metalsltd 0.145 23% 1246772 $8,749,344 HOR Horseshoe Metals Ltd 0.025 19% 670720 $14,070,141 BCA Black Canyon Limited 0.16 19% 405899 $17,502,844 ID8 Identitii Limited 0.007 17% 15000 $4,668,081 In the news... Horseshoe Metals (ASX:HOR) is preparing to fire up its direct shipping ore operations for the Horseshoe Lights copper-gold project in WA, after getting the greenlight from the DEMIRS. HOR expects to have boots on the ground within the next few weeks, with sales of existing copper stockpiles to begin shortly thereafter. It's perfect timing for the company, with the price of copper soaring more than 26% in the year to date to reach 10-year highs. Latitude 66 (ASX:LAT) is offloading its 17.5% interest in the Greater Duchess joint venture project, triggering a right of first refusal for JV partner Carnaby Resources (ASX:CNB). LAT is looking to sell its interest for $2m, with some conditional payments on the table of up to $4m in cash or ASX-listed shares. If the project is sold within 90 days of the sale and anyone can get their hands on 100% of the project interest, LAT will be $4m richer; if only a partial sale is made in that time, the company will earn 50% of any proceeds above $4m. LAGGARDS Code Name Last % Change Volume Market Cap AOA Ausmon Resorces 0.001 -50% 111800 $2,622,427 VHL Vitasora Health Ltd 0.03 -23% 3864299 $61,504,061 MMR Mec Resources 0.004 -20% 504034 $9,248,829 PIL Peppermint Inv Ltd 0.002 -20% 100000 $5,752,724 C29 C29Metalslimited 0.015 -17% 1772692 $3,135,388 CUS Coppersearchlimited 0.016 -16% 100593 $3,018,941 RDS Redstone Resources 0.003 -14% 150000 $3,619,936 RNX Renegade Exploration 0.0035 -13% 616666 $5,153,454 CPV Clearvue Technologie 0.14 -13% 368291 $42,980,027 NYM Narryermetalslimited 0.031 -11% 101959 $6,161,918
News.com.au
23 minutes ago
- News.com.au
Health Check: Like bloodthirsty sharks, offshore acquirers are circling cheap biotech assets
As today's Medadvisor deal attests, underperforming biotech assets are getting a bite or two Next Science shares continue to rally, but the company is still valued at less than Demant's offer price for most of its assets Neurizon enters a key deal with the supplier of its drug candidate for motor neurone disease Inspired by the 50 th anniversary of the original Jaws movie, local and offshore predators are on the hunt for local biotech prey. Today, medication compliance group MedAdvisor (ASX:MDR) said it had entered a binding agreement to sell its Australian ops to the Canadian owned Jonas Software, for a headline $35 million. As we reported yesterday, Medadvisor was the worst performing ASX-listed biotech last financial year, sinking 82%. Yesterday, struggling wound management company Next Science (ASX:NXS) proposed a US$50 million ($75 million) deal to sell most of its assets. The buyer is the Milan based Demetra Holdings (see below). Mayne Pharma (ASX:MYX) is – or was – subject to a $600 million offer from US dermatology group Cosette, but the suitor spat out the arm after due diligence (allegedly) revealed horrors lurking in depths. As with the makers of the epic Jaws movie, we must apologise to the sea's apex predators for besmirching their reputation. Unlike with the six remarkably careless Jaws 1 victims, biotech's metaphorical equivalent is usually most welcome. Medadvisor prefers US focus Coming back to Medadvisor, the company wants to focus on its bigger US business, which provides prescription drug information services to patients via big pharma and chemists. The terms are like the non-binding ones announced on May 9. One quirk is that the deal includes the Medadvisor moniker, but Medadvisor can continue to use that name under a royalty-free arrangement. Still, the company will seek shareholder approval to change its name. While Medadvisor pockets $35 million now, it has dibs on an 'uncapped contingent consideration' based on the divested arm's performance. On current trends, the company would expect another $7.35 million. Medadvisor intends to use some of the proceeds to discharge a $23.5 million finance facility. The company will use the remainder pending a review of its US operations, which have been hit by a downturn in vaccination rates. This has resulted in the jab makers winding back promotional spend. Next Science investors retain zeal for deal Having pushed up Next Science shares 64% yesterday, investors today added another 9% on the back of the proposal that in effect will see their company disappear. The proposal is subject to the consent of Next Science shareholders at a meeting scheduled on August 14. In framing the friendly deal, Demetra no doubt has chatted to Next Science's 37% shareholder, property tycoon and biotech dabbler Lang Walker. The deal is also subject to an independent expert report. Next Science intends to redistribute to shareholders the estimated US$30 million remaining after winding up costs. With approved products in the US, Next Science operates in wound care and surgical infection control. Demetra supplies bone cement, for fixing orthopaedic implants and the like. Next Science's regally dubbed CEO, Harry Hall IV says that in Demetra's more capacious hands Next Science's products 'will be better positioned to realise their full potential in improving patient care globally'. Next Science listed at $1 in April 2019 in a $35 million IPO and peaked at close to $2 in mid 2021. It's been downhill from there. Meanwhile the ASX circle of life continues, with wound management house Tetratherix (ASX:TTX) listing successfully last Monday. Interestingly, Next Science still bears a market cap of a mere $34 million. Neurizon does 'vet' deal but it's not going to the dogs The developer of a repurposed drug candidate for a form of motor neurone disease, Neurizon Therapeutics (ASX:NUZ) has entered an exclusive global licensing agreement with the New York-listed Elanco Animal Health. The deal doesn't take Neurizon back into veterinary drugs, the company's key remit when it was known as Pharmaust. But Elanco is the exclusive maker of the drug candidate – monepantel – which regulators originally approved as a sheep drench. Monepantel is the active component of NUZ-001, Neurizon's lead therapy for amyotrophic lateral sclerosis (ALS) and other human neurodegenerative diseases. The deal bestows Neurizon with the global rights for Elanco's intellectual property, including extensive non-clinical (animal) and manufacturing data. The agreement also outlines key terms for Elanco's future supply of monepantel, with a formal agreement expected in the current half. Monepantel works by inhibiting the mTOR signalling pathway, which plays a central role in the growth of cancer cells and the degeneration of neurons. mTOR stands for the 'mechanistic Target of Rapamycin', a reference not to a Tolkien novel but a well-known oncology target (rapamycin). Neurizon is participating in Healey ALS, a collaborative MND trial across 70-plus sites in the US. The platform will test several drugs simultaneously, thus increasing patient access and reducing study costs and completion and enrolment times. Neurizon CEO Dr Michael Thurn says the deal should 'dramatically reduce near-term development costs and accelerate development timelines.' The deal involves a nominal up-front payment and back-ended development milestones of US$9.75 million for the initial product. Should sales take off, Neurizon pays sales milestones of up to US$65 million but we'll cross that bridge when we come to it. Emvision's Emu hops to five sites, with one more to come The developer of a portable bedside stroke scanner dubbed Emu, EMvision Medical Devices (ASX:EMV) hopes to sign up its sixth and final site for its pivotal trial pitched at regulatory approval. The company today said five sites – three in the US and two locally – were now 'actively enrolling and scanning patients'. The three US sites are New York's Mt Sinai Hospital, Florida's Mayo Clinic and UT Health Memorial Hermann Texas Medical Centre. The local sites are Royal Melbourne Hospital and Sydney's Liverpool Hospital. The sixth site, at a west coast US clinic, should be announced 'shortly'. Emvision also won assent to start a continuous innovation study for stroke and traumatic brain injury patients, at Newcastle's John Hunter Hospital and Brisbane's Princess Alexandra Hospital. The trial involves enrolling up to 300 suspected stroke victims. Clinicians will assess them in the normal manner along with an Emu scan. The study aims to determine accurately whether a stroke is a blood clot or a bleed. If Emu takes flight, the company plans to seek expedited US approval for an ambulance variant, called First Responder.
News.com.au
an hour ago
- News.com.au
China flexing its muscles in ways that ‘differ from Australia's interests'
China is 'asserting its influence' in ways that do not align with Australia's national interest, Foreign Minister Penny Wong says. Senator Wong is in Washington for a Quad summit with her Indian, Japanese and US counterparts. The Quad is a partnership broadly seen as a check on China's economic and increasingly militaristic might. Fronting media on Wednesday (AEST), Senator Wong said the four countries were under no illusions about the threats posed by China. 'China is a great power,' she told reporters in the US capital. 'It is asserting its influence using all aspects of national power. 'The challenge for Australia and for other countries is that … one can see where those interests differ from Australia's interests.' Pacific power grabbing and threatening freedom of navigation are among Canberra's key grievances with Beijing. The Albanese government has spent billions on countering China's efforts to boost its sway in the region, including by debt-trapping Australia's smaller Pacific neighbours. The Chinese government has also stepped up military activity in the South China Sea and around the democratically self-governed island of Taiwan, threatening key shipping lanes that Australia depends upon. 'Certainly … China has interests, which it presses, which are not the same as our interests,' Senator Wong said. 'And we have to navigate that, and we do that and we have not stepped back as a government from those things where we disagree, but we will continue to engage.' She repeated the Albanese government's mantra on China, saying 'we co-operate where we can, disagree where we must'. Despite the tough words, Senator Wong said she and State Secretary Marco Rubio did not discuss Australia's defence spending. The Trump administration last month requested the Albanese government hike the military budget to 3.5 per cent of GDP. The demand ignited a furious debate that has somewhat poured cold water on Anthony Albanese's post-election high amid severe scrutiny over his relationship with Donald Trump. 'The issue of Australia's defence budget was not raised with me, either in the Quad or in my bilateral meeting,' Senator Wong said. 'What we did discuss is a number of areas of co-operation that we want to see more concrete outcomes … critical minerals is one of them, maritime security is another.'
